(MENAFN- GlobeNewsWire - Nasdaq) The digital therapeutics market offers opportunities in chronic disease management, mental health, and remote monitoring, fueled by regulatory advances and AI-driven personalization. Growth potential lies in partnerships, integration with care pathways, and global expansion, but success hinges on evidence generation, patient engagement, and regulatory navigation.

Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Digital Therapeutics Market Outlook 2026-2034: Market Share, and Growth Analysis" report has been added to ResearchAndMarkets's offering.
The Digital Therapeutics Market is valued at USD 9.94 billion in 2025 and is projected to grow at a CAGR of 22.4% to reach USD 61.29 billion by 2034.
Major trends include increased integration of digital-therapeutics platforms into healthcare systems and reimbursement pathways, the use of AI/ML for adaptive and personalised therapy, growth of combined therapy modalities, rise of remote patient monitoring and tele-health convergence, and regulatory advancements (regulatory clarity, FDA digital-therapeutics authorisations, real-world evidence requirements).

Growth is propelled by rising chronic-disease burden, increasing healthcare costs, shifting care to outpatient/home settings, adoption of remote/virtual care accelerated by the COVID-19 pandemic, and greater payer/investor interest in digital health solutions. On the competitive side, companies span pure-play DTx platforms, health-tech firms, pharma/biotech partnerships, and digital-device providers.

Success factors include clinical efficacy and evidence-generation, regulatory clearance, interoperability with electronic-health-records (EHRs), patient engagement/retention, and ability to secure reimbursement. Additional market dynamics include issues around data security/privacy, demonstration of long-term outcomes/value, competition from wellness apps, digital-health fatigue, and varying regulatory/reimbursement frameworks across regions.
Digital Therapeutics Market Key Insights

• Chronic disease management is a major value pool: Digital therapeutics targeting conditions such as diabetes, cardiovascular disease, respiratory disorders and obesity offer high value propositions because of large patient populations, high treatment costs, and potential for improved outcomes/cost savings.
• Mental health and behavioural therapy segments growing fastest: Conditions like insomnia, anxiety, depression and substance use disorders are well suited to digital therapeutics delivery via apps or VR, with lower barriers to entry and strong patient acceptance, making them high growth niches.
• Regulatory and reimbursement evolution is crucial: As regulators define frameworks for digital therapeutics authorisation (e.g., software as medical device) and payers begin reimbursement pilots, adoption accelerates significantly; early movers with regulatory clear products gain advantage.
• Evidence generation differentiates winners: Clinical trials, real world evidence, outcomes data and peer reviewed studies support credibility and uptake - products with stronger evidence secure clinician/payer trust and partnerships with pharmaceutical companies.
• Integration with care pathways and wearable/device ecosystems adds value: Digital therapeutics linked to wearables, sensors or connected devices (e.g., insulin pumps, lung function monitors) and integrated into clinical workflows (EHRs, tele health platforms) enhance engagement and clinical relevance.
• Home care and remote monitoring trends accelerate adoption: The shift from in clinic treatment to home based care (especially post pandemic) increases demand for digital therapeutics that deliver remote therapy, real time monitoring and patient engagement tools.
• Patient engagement & retention are critical challenges: Unlike conventional therapies, digital therapeutics success hinges on sustained patient use and adherence; platforms that employ gamification, behavioural design, personalised content and trigger interventions outperform.
• Partnerships and hybrid models drive scale: Collaborations between digital therapeutics vendors, pharmaceutical/biotech companies, payers, and healthcare systems enable scale up, co branding, and bundling of software device therapy combinations, unlocking broader market access.
• Global expansion and localisation matter: While North America and Europe lead early adoption, emerging markets offer growth potential; localisation of language, reimbursement pathways and health system integration is essential to scale internationally.
• Data privacy, cybersecurity & digital health fatigue pose risks: Handling of health data, compliance with privacy regulations (HIPAA, GDPR), and maintaining patient trust are essential; additionally, user fatigue or drop off from digital health apps can hamper retention and outcomes.

Your Key Takeaways from the Digital Therapeutics Market Report

• Global Digital Therapeutics market size and growth projections (CAGR), 2024-2034
• Impact of Russia-Ukraine, Israel-Palestine, and Hamas conflicts on Digital Therapeutics trade, costs, and supply chains
• Digital Therapeutics market size, share, and outlook across 5 regions and 27 countries, 2023-2034
• Digital Therapeutics market size, CAGR, and market share of key products, applications, and end-user verticals, 2023-2034
• Short- and long-term Digital Therapeutics market trends, drivers, restraints, and opportunities
• Porter's Five Forces analysis, technological developments, and Digital Therapeutics supply chain analysis
• Digital Therapeutics trade analysis, Digital Therapeutics market price analysis, and Digital Therapeutics supply/demand dynamics
• Profiles of 5 leading companies - overview, key strategies, financials, and products
• Latest Digital Therapeutics market news and developments

Key Attributes:

Report Attribute	Details
No. of Pages	160
Forecast Period	2025 - 2034
Estimated Market Value (USD) in 2025	$9.94 Billion
Forecasted Market Value (USD) by 2034	$61.29 Billion
Compound Annual Growth Rate	22.4%
Regions Covered	Global

Companies Featured

• Akili
• Omada Health
• Propeller Health
• Kaia Health
• Twill (Happify)
• Click Therapeutics
• Big Health
• Better Therapeutics
• Hinge Health
• Noom
• Virta Health
• Biofourmis
• Sword Health
• Welldoc
• Pear Therapeutics

Digital Therapeutics Market Segmentation

By Offering

• Programs
• Software/Platforms
• Virtual Reality/Games

By Revenue Modal

• Subscription
• One time Purchase/Licensing
• Outcome/Value based

By Sales Channel

• B2C
• B2B

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Digital Therapeutics Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN13112025004107003653ID1110340357